As global health communities have mobilized to find a robust response to the coronavirus pandemic, those at the frontlines of the fight against cancer have continued to prevent, diagnose, treat and monitor the disease amid unprecedented disruption. Their ultimate goal: find a cure.
How is the Biden administration, aiming to “end cancer as we know it,” advancing treatments, screenings and survival rates? How can emerging technologies like artificial intelligence and cell therapy be used in the fight? And what are lawmakers, physicians and insurers doing to eliminate disparities in high-quality healthcare access and affordability?
Wednesday, October 6, 2021
1:00PM ET / 10:00AM PT
- Sen. Roy Blunt (R-MO), Chair, Senate Republican Policy Committee; Cancer Survivor
- Rep. Bonnie Watson Coleman (D-NJ), Member, Appropriations Committee; Cancer Survivor
- William G. Cance, MD, Chief Medical and Scientific Officer, American Cancer Society
- Dr. Gerald Harmon, President, American Medical Association
- Dr. Ronda Henry-Tillman, Chief of Breast Oncology, University of Arkansas for Medical Sciences
- Dr. Anirban Maitra, Co-lead, Pancreatic Cancer Moonshot & Scientific Director, Pancreatic Cancer Research Center, MD Anderson Cancer Center
- Dr. Edith P. Mitchell, Member, President’s Cancer Panel; Director, Center to Eliminate Health Disparities & Associate Director of Diversity Affairs, Sidney Kimmel Cancer Center, Thomas Jefferson University
- Dr. Edith Perez, Serene M. and Frances C. Durling Professor of Medicine, Mayo Clinic College of Medicine; Chair, Health Equity Committee, Stand Up to Cancer
- Dr. Norman Sharpless, Director, National Cancer Institute
- Dr. Karen Winkfield, Ingram Professor of Cancer Research, Vanderbilt-Ingram Cancer Center; Executive Director, Meharry-Vanderbilt Alliance
Phil Febbo, MD, Chief Medical Officer, Illumina
- Steve Clemons, Editor-at-Large, The Hill
Questions for our speakers? Tweet us: @TheHillEvents using #TheHillCureCancer
SPONSORED CONTENT MESSAGE:
Cancer is a disease of the genome. Illumina’s sequencing technology provides doctors and patients with the deep genomic information they need to plan for treatment and care. As targeted therapies become the new standard in cancer care, DNA sequencing will play a critical role in the selection of treatment. Learn more about Illumina’s mission to improve human health by unlocking the power of the genome at illumina.com.